Evidence map›Paper›PMID 41609866›Full record

ArticleCell biology and toxicology2026

Acute myeloid leukemia (AML)-derived bone mesenchymal stem cell exosomal METTL14 promotes AML cell growth and glycolysis by HOXA3/WNT7B axis.

Wanying Liu, Xi Ming, Jiaying Wu, Sijia Yan, Shuai Su, Rubing Zheng, Yu Wang, Yi Xiao

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell biology and toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Wanying Liu *Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, No.1095 Jie-Fang Avenue, Wuhan , Hubei, 430030, China.
Xi Ming *Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, No.1095 Jie-Fang Avenue, Wuhan , Hubei, 430030, China.
Jiaying WuDepartment of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, No.1095 Jie-Fang Avenue, Wuhan , Hubei, 430030, China.
Sijia YanDepartment of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, No.1095 Jie-Fang Avenue, Wuhan , Hubei, 430030, China.
Shuai SuDepartment of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, No.1095 Jie-Fang Avenue, Wuhan , Hubei, 430030, China.
Rubing ZhengDepartment of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, No.1095 Jie-Fang Avenue, Wuhan , Hubei, 430030, China.
Yu WangDepartment of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, No.1095 Jie-Fang Avenue, Wuhan , Hubei, 430030, China.
Yi XiaoDepartment of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, No.1095 Jie-Fang Avenue, Wuhan , Hubei, 430030, China. yixiao@tjh.tjmu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acute myeloid leukemia (AML)-derived bone mesenchymal stem cell (MSC) exosomes have been confirmed to have a positive effect on AML progression. This study aim to reveal the underlying molecular mechanism by which AML-MSC-derived exosomes promotes AML progression. AML-MSC was isolated from the bone marrow aspirates of AML patients. After incubated with AML-MSC, AML cell functions were analyzed. The expression levels of methyltransferase-like 14 (METTL14), homeobox A3 (HOXA3), WNT family member 7B (WNT7B) and glycolysis-related markers were examined. Exosomes were isolated from AML-MSC and then the obtained exosomes were co-cultured with AML cells. AML-MSC co-culturing could enhance AML cell proliferation and glycolysis, while repress cell apoptosis. METTL14 was upregulated in exosomes from AML-MSC, which could be ingested by AML cells. METTL14 could enhance HOXA3 mRNA stability via promoting its m6A modification. Knockdown of exosomal METTL14 from AML-MSC inhibited AML cell growth and glycolysis, while were reversed by HOXA3. In addition, HOXA3 bound to WNT7B promoter to increase its transcription, and WNT7B overexpression also eliminated si-HOXA3-mediated inhibitory on AML cell growth and glycolysis. Animal study revealed that knockdown of exosomal METTL14 from AML-MSC reduced AML tumorigenesis by decreasing HOXA3 and WNT7B expression. AML-MSC-derived exosomal METTL14 facilitated AML cell growth and glycolysis by activating the HOXA3/WNT7B axis, providing a new mechanism for understanding AML-MSC-derived exosomes to promote AML progression.

Indexed as

ExosomesGlycolysisHomeodomain ProteinsLeukemia, Myeloid, AcuteMesenchymal Stem CellsMethyltransferasesWnt ProteinsAnimalsCell Line, TumorCell ProliferationHumansMaleHomeodomain ProteinsMethyltransferasesWnt ProteinsAcute myeloid leukemiaBone mesenchymal stem cellsExosomeMETTL14

Identifiers

PMID41609866
PMCPMC12894161

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.